Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 2, 2006

EvoGenix and NIH Team-up to Develop Antibody Therapies Against PAMP

  • EvoGenix will work with the NIH under a CRADA to provide tailored antibodies against PAMP, a small protein shown to be a vital factor in angiogenesis. “It appears that PAMP-related proteins act earlier in blood vessel formation than the target for Avastin, VEGF,” explains Alfredo Martinez, Ph.D., of the Cajal Institute, “so that inhibitory antibodies provided by EvoGenix may provide broader suppression than Avastin of new blood vessel growth."

    Scientists at the NCI will carry out testing and initial clinical evaluation of these new anticancer therapeutics. EvoGenix says that it was selected as the partner for the NCI team because of its ability to produce highly potent humanized antibodies suitable for therapeutic testing.

    "Imminent testing of our antibodies by the NCI team will confirm the value of this new approach to cancer therapy," explains Steffen Nock, president of the EvoGenix U.S. operations.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »